Roche’s Gazyva Nears EU Approval as Groundbreaking Lupus Nephritis Treatment

Roche’s drug Gazyva could soon become a new treatment option for lupus nephritis in the EU. The medication, already approved for lymphomas in 100 countries, has received a positive recommendation from the CHMP. A final decision from the European Commission is expected shortly.

Lupus nephritis is a severe kidney disease affecting around 1.7 million people globally, mostly women. Without effective treatment, up to a third of patients may develop end-stage kidney failure within a decade.

Gazyva (obinutuzumab) has shown promising results in clinical trials. The 'Regency' study found it outperformed the current standard therapy for lupus nephritis. This has led to the CHMP’s recommendation for EU-wide approval, which would cover all member states. Roche now awaits the European Commission’s final ruling. If approved, Gazyva would expand its use beyond lymphoma, offering a new option for patients with this debilitating condition.

The EU’s decision will determine whether Gazyva becomes available for lupus nephritis patients across Europe. If approved, it could help reduce the risk of kidney failure in a disease where current treatments often fall short. The drug’s existing approval for lymphomas suggests a strong safety and efficacy profile.